Sponsor Check › Issuer
Corporation · organized in DELAWARE · formed Over five years ago · NORMANDY PARK, WA · SEC CIK 1851853
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 22, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: Oct 23, 2026, 8:13 PM ET
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) · Last checked Oct 23, 2026, 8:13 PM ET.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:13 PM ET.
0 of 5 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $120,000.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 18, 2021 D File 021-392687 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Mar 30, 2022 D File 021-439622 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Apr 25, 2023 D File 021-479877 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Nov 1, 2024 D File 021-528464 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 22, 2026 D/A File 021-559876 | $0 | $0 | $120,000 | None listed |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D/A (amendment) filed Oct 22, 2026 · amends 0001851853-25-000002 ↗ SEC file no. 021-559876 · accession 0001851853-26-000001 |
|---|---|
| Raise progress | $4,009,945 sold of $5,000,000 offered (80%) · $990,055 remaining |
| Filing timing | Date of first sale: Sep 24, 2025 · Form D filed: Oct 22, 2026 (393 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 395 days (1.1 years) |
| Annual amendments | Issuer reported the offering may last more than one year. This filing is an amendment dated Oct 22, 2026. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 34 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
| Minimum investment accepted | $50,000 |
| Securities offered | Debt |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $120,000 |
| Signed by | Andrew Holman, M.D., CEO & Director (Oct 22, 2026) |
| Changes vs prior filing | total sold: $159,980 → $4,009,945 investors: 4 → 34 Compared with the D filed Oct 6, 2025 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $50,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $5,000,000. Typical range: $2,000,000–$14,000,000. Investors: 34. Typical range: 1–19. "Similar" = Biotechnology offerings claiming 506(c) filed in the last 5 years (163 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Oct 6, 2025 SEC file no. 021-559876 · accession 0001851853-25-000002 |
|---|---|
| Raise progress | $159,980 sold of $5,000,000 offered (3%) · $4,840,020 remaining |
| Filing timing | Date of first sale: Sep 24, 2025 · Form D filed: Oct 6, 2025 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 395 days (1.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 4 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
| Minimum investment accepted | $50,000 |
| Securities offered | Debt |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $120,000 |
| Signed by | Andrew Holman, M.D., CEO & Director (Sep 30, 2025) |
| Market context | Minimum investment: $50,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $5,000,000. Typical range: $2,000,000–$14,000,000. Investors: 4. Typical range: 1–19. "Similar" = Biotechnology offerings claiming 506(c) filed in the last 5 years (163 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 1, 2024 SEC file no. 021-528464 · accession 0001851853-24-000001 |
|---|---|
| Raise progress | $720,000 sold of $3,500,000 offered (21%) · $2,780,000 remaining |
| Filing timing | Date of first sale: Aug 23, 2024 · Form D filed: Nov 1, 2024 (70 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 792 days (2.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
| Minimum investment accepted | $20,000 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: No Revenues |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Andrew Holman, M.D., CEO & Director (Nov 1, 2024) |
| Market context | Minimum investment: $20,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $3,500,000. Typical range: $2,000,000–$14,000,000. Investors: 5. Typical range: 1–19. "Similar" = Biotechnology offerings claiming 506(c) filed in the last 5 years (163 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Apr 25, 2023 SEC file no. 021-479877 · accession 0001851853-23-000002 |
|---|---|
| Raise progress | $25,000 sold of $3,000,000 offered (1%) · $2,975,000 remaining |
| Filing timing | Date of first sale: Apr 14, 2023 · Form D filed: Apr 25, 2023 (11 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,289 days (3.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 0 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(c) — general advertising allowed; all investors must be verified accredited |
| Minimum investment accepted | $25,000 |
| Securities offered | Option, warrant or other right to acquire |
| Industry / issuer size | Biotechnology · revenue range: No Revenues |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Andrew Holman, M.D., CEO & Director (Apr 25, 2023) |
| Market context | Minimum investment: $25,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $3,000,000. Typical range: $2,000,000–$14,000,000. Investors: 0. Typical range: 1–19. "Similar" = Biotechnology offerings claiming 506(c) filed in the last 5 years (163 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 30, 2022 SEC file no. 021-439622 · accession 0001851853-22-000001 |
|---|---|
| Raise progress | $445,000 sold of $3,000,000 offered (15%) · $2,555,000 remaining |
| Filing timing | Date of first sale: Mar 17, 2022 · Form D filed: Mar 30, 2022 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,682 days (4.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Andrew J. Holman, CEO & President (Mar 30, 2022) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $3,000,000. Typical range: $829,831–$9,999,998. Investors: 6. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 18, 2021 SEC file no. 021-392687 · accession 0001851853-21-000001 |
|---|---|
| Raise progress | $470,000 sold of $2,000,000 offered (24%) · $1,530,000 remaining |
| Filing timing | Date of first sale: Mar 3, 2021 · Form D filed: Mar 18, 2021 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,061 days (5.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Andrew J. Holman, President and CEO (Mar 18, 2021) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $2,000,000. Typical range: $829,831–$9,999,998. Investors: 8. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months · most recent filing Oct 22, 2026 · industry as reported over time: Other Health Care → Biotechnology.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Andrew Holman, M.D. | Executive Officer, Director | WA | Apr 25, 2023 → Oct 22, 2026 | — |
| Bernie Tobin | Director | WA | Apr 25, 2023 → Oct 22, 2026 | — |
| Kevin Tracey, M.D. | Director | WA | Apr 25, 2023 → Oct 22, 2026 | — |
| Leroy Hood, M.D., Ph.D. | Director | WA | Apr 25, 2023 → Oct 22, 2026 | — |
| Ryan Sullivan, Ph.D. | Director | WA | Nov 1, 2024 → Oct 22, 2026 | — |
| Steven Daly, M.S., M.B.A. | Director | WA | Apr 25, 2023 → Oct 22, 2026 | — |
| Andrew J Holman | Executive Officer, Director | WA | Mar 30, 2022 | — |
| Bernie J. Tobin | Director | WA | Mar 18, 2021 → Mar 30, 2022 | — |
| Steven J. Daly | Director | WA | Mar 18, 2021 → Mar 30, 2022 | — |
| Andrew J. Holman | Executive Officer, Director | WA | Mar 18, 2021 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
No other issuers list the same related persons.
Shared address: this business address appears on no other issuer's filings in our index.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Inmedix, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.